Halozyme Therapeutics, Inc. (NASDAQ:HALO) Shares Acquired by Convergence Investment Partners LLC

Convergence Investment Partners LLC lifted its holdings in shares of Halozyme Therapeutics, Inc. (NASDAQ:HALO) by 25.9% in the fourth quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The fund owned 34,713 shares of the biopharmaceutical company’s stock after buying an additional 7,151 shares during the period. Convergence Investment Partners LLC’s holdings in Halozyme Therapeutics were worth $1,660,000 at the end of the most recent reporting period.

A number of other institutional investors have also modified their holdings of HALO. Louisiana State Employees Retirement System grew its position in Halozyme Therapeutics by 0.6% in the 4th quarter. Louisiana State Employees Retirement System now owns 35,300 shares of the biopharmaceutical company’s stock worth $1,688,000 after purchasing an additional 200 shares during the last quarter. Verdence Capital Advisors LLC boosted its holdings in shares of Halozyme Therapeutics by 1.9% in the third quarter. Verdence Capital Advisors LLC now owns 13,232 shares of the biopharmaceutical company’s stock valued at $757,000 after acquiring an additional 252 shares in the last quarter. State of New Jersey Common Pension Fund D boosted its holdings in shares of Halozyme Therapeutics by 0.6% in the fourth quarter. State of New Jersey Common Pension Fund D now owns 47,663 shares of the biopharmaceutical company’s stock valued at $2,279,000 after acquiring an additional 302 shares in the last quarter. Nations Financial Group Inc. IA ADV boosted its holdings in shares of Halozyme Therapeutics by 2.4% in the fourth quarter. Nations Financial Group Inc. IA ADV now owns 14,062 shares of the biopharmaceutical company’s stock valued at $672,000 after acquiring an additional 328 shares in the last quarter. Finally, Diversify Advisory Services LLC boosted its holdings in shares of Halozyme Therapeutics by 8.5% in the third quarter. Diversify Advisory Services LLC now owns 5,331 shares of the biopharmaceutical company’s stock valued at $305,000 after acquiring an additional 418 shares in the last quarter. Institutional investors own 97.79% of the company’s stock.

Insider Transactions at Halozyme Therapeutics

In related news, Director Jeffrey William Henderson sold 10,000 shares of the firm’s stock in a transaction on Monday, January 6th. The shares were sold at an average price of $50.01, for a total value of $500,100.00. Following the transaction, the director now directly owns 43,611 shares in the company, valued at approximately $2,180,986.11. This trade represents a 18.65 % decrease in their position. The transaction was disclosed in a filing with the SEC, which is available through this link. 2.70% of the stock is currently owned by company insiders.

Halozyme Therapeutics Stock Down 0.7 %

HALO stock opened at $57.90 on Wednesday. Halozyme Therapeutics, Inc. has a 12-month low of $35.50 and a 12-month high of $65.53. The company has a quick ratio of 9.15, a current ratio of 10.36 and a debt-to-equity ratio of 3.32. The company has a market cap of $7.37 billion, a price-to-earnings ratio of 19.17, a PEG ratio of 0.44 and a beta of 1.25. The company has a 50 day moving average of $52.69 and a two-hundred day moving average of $54.51.

Halozyme Therapeutics (NASDAQ:HALO) last announced its quarterly earnings results on Tuesday, February 18th. The biopharmaceutical company reported $1.19 EPS for the quarter, topping the consensus estimate of $1.17 by $0.02. Halozyme Therapeutics had a net margin of 41.43% and a return on equity of 179.82%. On average, equities analysts anticipate that Halozyme Therapeutics, Inc. will post 3.87 earnings per share for the current fiscal year.

Analyst Ratings Changes

Several analysts recently commented on the stock. Wells Fargo & Company cut their target price on shares of Halozyme Therapeutics from $62.00 to $57.00 and set an “equal weight” rating for the company in a research note on Monday, January 13th. Piper Sandler increased their target price on shares of Halozyme Therapeutics from $52.00 to $53.00 and gave the company a “neutral” rating in a research note on Friday, January 10th. JMP Securities increased their target price on shares of Halozyme Therapeutics from $72.00 to $73.00 and gave the company a “market outperform” rating in a research note on Friday, November 1st. Finally, HC Wainwright restated a “buy” rating and issued a $70.00 price target on shares of Halozyme Therapeutics in a research report on Tuesday, February 4th. Four research analysts have rated the stock with a hold rating and seven have assigned a buy rating to the company. According to data from MarketBeat.com, the company has an average rating of “Moderate Buy” and an average price target of $60.89.

About Halozyme Therapeutics

Halozyme Therapeutics, Inc, a biopharma technology platform company, researches, develops, and commercializes proprietary enzymes and devices in the United States, Switzerland, Belgium, Japan, and internationally. The company's products are based on the patented recombinant human hyaluronidase enzyme (rHuPH20) that enables delivery of injectable biologics, such as monoclonal antibodies and other therapeutic molecules, as well as small molecules and fluids.